Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ARV IVRs in Healthy Women
NCT02431273Phase 1Completed
- Sponsor
- Auritec Pharmaceuticals, Inc.
- Start
- Jun 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tenofovir disoproxil fumarate, emtricitabine and maraviroc in human immunodeficiency virus infection (HIV), sponsored by Auritec Pharmaceuticals, Inc. Primary endpoints: Number of Participants With Specific Graded Adverse Events, Pharmacokinetics in Cervicovaginal Fluid at Day 7 and 4 more. Started Jun 2015; status: completed.
02
Drugs
tenofovir disoproxil fumarateemtricitabinemaraviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02431273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431273.